How Often Does Pancreatitis Occur with Mounjaro?

What the SURMOUNT trials recorded — and how to read those numbers honestly

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks. Cases of acute pancreatitis did occur in the tirzepatide arms, but at low absolute rates, and, critically, rates that were not dramatically higher than in the placebo group. That is the pattern regulators look for when assessing whether a medicine causes a condition or whether the condition appears in an overweight population regardless of treatment. The NICE appraisal of tirzepatide (TA1026) reviewed the full SURMOUNT evidence base and reached a positive benefit-risk conclusion, which would not have been possible if pancreatitis rates had been alarming.

That does not mean the risk is zero. Pancreatitis is listed in the Mounjaro Summary of Product Characteristics as an adverse reaction, and our detailed resource on Mounjaro and pancreatitis explains how that classification is arrived at and what it means in practice. The signal is real; the frequency classification reflects how often it was observed across controlled trial participants. For context on how those classifications map onto clinical practice, the NHS tirzepatide medicines page sets this out in plain language alongside the full side-effect profile.

One practical checking habit worth building: before each weekly injection, briefly note whether you have had any new or unusual abdominal discomfort during the past week. It takes under a minute and means you are not trying to recall a week's worth of symptoms if a prescriber asks.

Why pancreatitis deserves specific attention on GLP-1 medicines

GLP-1 receptors are expressed in pancreatic tissue, which is why researchers have examined pancreatitis risk across the entire class, semaglutide, liraglutide and tirzepatide alike. The biological plausibility has always been there. What decades of trial and post-marketing data have shown is that acute pancreatitis does occur, but chronic pancreatitis and pancreatic cancer have not been demonstrated to increase, a distinction that matters when discussing long-term use. The NHS England guidance on weight-management injections acknowledges pancreatitis as a known risk while placing it in the context of the broader benefit-risk balance that led to Mounjaro's licence.

People with a personal or family history of pancreatitis, or with gallstone disease (itself a risk factor for acute pancreatitis), should discuss this explicitly during their clinical assessment. That conversation is not a box-ticking exercise. A prescriber who knows your history can weigh whether Mounjaro is appropriate for you, or whether a different approach makes more sense. Our overview of Mounjaro's side effects covers the full profile for anyone who wants to read across the broader safety picture before their consultation.

When to get medical help, and what exactly to watch for

The symptom pattern that should prompt immediate action is severe abdominal pain that is persistent rather than transient, often centred in the upper abdomen, and that may radiate through to the back. It can be accompanied by nausea or vomiting, though not always. It does not behave like the mild nausea that many people experience in the first week or two of treatment, which tends to be low-grade and tied to eating. Pancreatitis pain is typically more intense, comes on more suddenly, and does not ease with a change in position.

If you experience that pattern, do not finish the current injection cycle and wait for a routine review. Stop taking Mounjaro and seek urgent medical attention, call 111 if you are unsure, or 999 or A&E if the pain is severe. This is consistent with the guidance issued in the MHRA's January 2026 Drug Safety Update, which was sent to all healthcare professionals prescribing across the GLP-1 class. Our guide to the risk of pancreatitis with Mounjaro covers the mechanistic and clinical picture if you want to read further. For those wondering about pre-existing pancreatic history specifically, the question of whether Mounjaro is appropriate if you have had pancreatitis before is addressed separately.

How suitability is assessed at the consultation stage

Prescribers look at pancreatitis risk as part of a structured clinical review, not as an afterthought. At nume, every consultation is personally read by a GPhC-registered Independent Prescriber (a real clinician, not automated decision-making) before any treatment is approved. If you have a history of gallstones, alcohol-related conditions, hypertriglyceridaemia, or prior pancreatitis, your prescriber needs to know. The consultation is the right place to raise these details, and our prescribers discuss both suitability and the specific side-effect profile as a standard part of that process.

If you are currently on Mounjaro through another provider and want to understand your ongoing risk, our Mounjaro treatment page gives a grounded overview of the medicine and how our clinical process works. You can also explore all weight-loss treatment options if you are still at the stage of deciding whether Mounjaro is right for you at all. The broader question of how common pancreatitis is with Mounjaro goes into further frequency detail for those who want to see the numbers in context.